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Discourse on safe drug use:  symbolic logics and ethical aspects 
 
Sylvie FAINZANG, 
INSERM (Cermes3), Paris 
 
 
Abstract:  
Drug safety is not a matter for healthcare professionals alone.  As actors, patients are also concerned, at 
three different levels:  1) with regard to their behaviour and choices of drugs, with a view to reducing 
adverse reactions, 2) with regard to the discourse sometimes used by doctors in relation to prescribed drugs, 
3) with regard to the discourses of the pharmaceutical industry concerning how they use their drugs within 
the framework of self-medication. We will examine these aspects on the basis of data gathered in France 
during anthropological studies on drug use.  
1. Patients’ concerns about reducing adverse effects give rise to a series of behaviours relating to drug use. 
They start with the identification of what they regard as a risk inherent in the substances or linked to 
uncontrolled use of drugs and try to neutralize their risks by modifying or modulating the prescriptions in 
line with various parameters.  They take into account dimensions as varied as: the nature of the prescribed 
drugs, the quantity, the dosage and the preservation of certain functions or organs, and follow their own 
rules of conduct in order to reduce risks. These dimensions bring into play both representations of the drug 
and representations of the person, and consider the effects or the risks of drugs in their physical, psychic, 
behavioural and social aspects.  
2. We consider here doctors’ discourse towards patients regarding the risks and possible effects of drugs, in 
particular the discourse of those who choose to hide the undesirable effects of drugs from their patients – or 
even to lie to them on this subject – with the aim of not jeopardizing the patient’s compliance. This 
situation involves comparing two logics:  ethics of care versus ethics of information. 
3. Regarding the pharmaceutical industry’s discourse on self-medication and risks.  Although it promotes 
self-medication on the basis of patients’ growing desire for autonomy and competency, the pharmaceutical 
industry has a discourse which stigmatizes the home medicine cabinet for reasons of safety, which in fact 
questions patients’ ability to use drugs properly. 
This analysis shows that the various behaviours and discourses relating to the risks of drugs are 
impregnated with symbolic, ethical and cultural logics. As a consequence, above and beyond works carried 
out on the question of pharmacovigilance, examining the issue of safe drug use involves studying the 
human (social and cultural) aspects which govern part of the discourses and practices relating to drug 
safety.   
 
 
 
The issue of drug safety is an important one, not only for health professionals but also for 
patients.  Indeed, if one takes into consideration the definition that Théophile & Bégaud (1) 
propose, which considers pharmacovigilance as “part of pharmaco-epidemiology devoted to 
managing and preventing risks” (p. 120), pharmacovigilance clearly comes across as an activity 
falling within the competency of professionals:  “pharmacovigilance covers all activities aimed at 
detecting, evaluating, quantifying, preventing the harmful effects of drugs, and at optimizing the 
benefit/risk ratio through adapted, individual or collective decisions:  to prescribe a drug or not, to 
adapt or to interrupt a treatment, to modify the indications of the drug or the information given to 
doctors or patients, or even to withdraw the drug from the market”.  
 However, patients are also concerned about reducing the risks of drugs, given that they 
manage their prescriptions so as to limit or avoid risks related to the consumption of drugs which 
are likely to have adverse effects, even though the logics on which they are based cannot be 
identified with those of the professionals.  Whilst it is of course not in patients’ power to 
withdraw any drugs from the market, they can nevertheless remove them from their shopping 
basket.  On the other hand, doctors do have a discourse directed towards patients about drug risks, 
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and what they choose to say raises questions of both a medical and an ethical nature.  Finally, the 
industry also has a discourse directed towards patients, not only through drug inserts, but also in 
the debates on drugs which take place in the public sphere, in particular on self-medication.  
 This paper focuses on certain discourses and practices with regard to the issue of risks of 
pharmaceuticals, 1) regarding the behaviours patients adopt to reduce the adverse effects of the 
drugs, 2) regarding what some doctors say to patients about drug risks, 3) regarding what the 
pharmaceutical industry says about self-medication and risks.  Overall, this insight will allow us 
to underline the symbolic logics and the ethical aspects which are at stake.  The data come from 
three anthropological research projects in France:  one on patients’ relationships with drugs 
according to their religious-cultural origin, the second concerning the information passed between 
patients and doctors, including information relating to pharmaceuticals and the third on self-
medication. 
 The purpose of anthropology is the explanatory and comparative study of the social and 
cultural characteristics of human groups. It starts by taking an in-depth look at a small group of 
people, analysing their discourses and practices. It is the latter which provide the data used for 
qualitative analysis, which are collected through long-term observation in order to identify – 
through the gestures, speech and actions of individuals, along with their recurrence and meaning 
within a given context – what this says about their logics and systems of thinking. At the 
methodological level, anthropology is largely based on monographs and case studies. On the 
basis of the data collected, it does not pretend to provide results which are statistically 
representative, but aims to uncover trends which allow us to reveal both the constants and the 
differences between the individuals and groups under study. In this respect, Hamel (2) makes the 
distinction between “statistical representativeness” and “theoretical representativeness”, echoing 
Marcel Mauss (3), for whom “It is an error to believe that the credence a scientific proposal 
deserves closely depends on the number of cases believed able to verify it” (p. 391). A distinction 
is made between the object of the study (a given cultural group) and the group of informants 
which represents it and which serves as an observatory. The sample is constructed using what 
Hamel (4) calls “methodological imagination”, where the case under study has the 
epistemological qualities that enable it to “represent” the group as a whole and which allow 
generalisation. As Bourdieu (5) said, “a single, well-constructed case ceases to be particular”.   
 
Patients’ behaviours 
 
 The patients’ concern for reducing adverse effects gives rise to a series of behaviours (rules of 
conduct) which go from the modification of medical prescriptions to the refusal to follow them, 
liable to be labelled as non-compliance behaviours by medical doctors.  Starting from an 
identification of what they regard as a risk inherent in the substances, or linked to uncontrolled 
use of drugs (even when they are prescribed), patients try to neutralize these risks by modifying 
or modulating the prescriptions in line with various parameters.  
The data on which this analysis rests have been collected within the framework of a study 
carried out in France on the behaviour of patients with regard to drugs (6).  The study was carried 
out among four groups of patients from different religious backgrounds:  Catholic, Protestant, 
Jewish and Muslim.  This qualitative study consisted of interviews and observations, both in 
hospital settings and in patients’ homes. The aims of the study were to determine what 
representations these subjects had of drugs in general and psychotropic drugs in particular, on 
what basis they do or do not use them, and what stands in the way of their use. Subjects were 
chosen on the basis of their families’ religious background and not of their belonging to an 
organized religion. The originality of the study was that it measured the “imprint” left by culture 
(and family religious background is part of culture) among patients who were sometimes totally 
unfamiliar with any religious beliefs. The study shows that religious-cultural background 
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influences representations about psychotropic drugs, about the body and about medical authorities 
through the espousal by individuals of the primordial values passed on in their families, a product 
of their cultural heritage. The research was carried out over a period of five years among 186 
patients belonging to diverse socio-professional categories. This study does not pretend to define 
Protestant behaviour compared to Catholic, Jewish or Muslim behaviour, not just because the 
collected data have no statistical value, but also because it is not possible to totally separate the 
cultural variable from the other variables. The study has the more modest aim of revealing trends, 
which can be objectivised through the observation of recurrences within the same cultural milieu, 
here defined as the fact of having a common religious origin, and observed among persons of 
diverse social milieus.  In this respect, patients from equivalent socio-professional categories 
were compared across those four cultural groups in order to neutralize the strictly sociological 
variable.   
 Risk-management techniques differ according to the patients, because they are in keeping with 
their cultural belonging, mobilizing various cultural representations. They take into account 
dimensions as varied as the nature of the prescribed drugs, the preservation of certain functions or 
organs, the quantity and the dosage of the drugs consumed.  
 Patients also try to limit the use of drugs suspected to have adverse effects on a given part of 
their body or on a given function or capacity. In this respect, although psychotropic drugs (be 
they neuroleptics, anti-depressants, tranquillizers or hypnotics) are reportedly consumed 
extensively in France (7) (8) – an over-consumption which is largely explained by over-
prescription – there is a great deal of reluctance to take them, due to various types of fear:  fear of 
physiological or psychological dependence, fear of changes in cognitive abilities, fear of a change 
in personality or of feeling sick.  
 Patients of Muslim origin express reluctance to take psychotropic drugs due to the harmful 
effects they suspect these substances to have on their body and on social behaviour through their 
deleterious effects on the heart. For instance, a teacher in electronic engineering considers that 
psychotropic drugs “act negatively on the heart and mind”. “With such drugs, one is no longer 
responsible for what one does; one becomes mad”, he says. This idea refers to a recurrent 
conception of the heart, which has a special quality for Muslim families, as witnessed by the 
people’s daily behaviour. To understand why they show such specific behaviour regarding the 
heart, it is necessary to stress what the heart represents for Muslim families. There are many 
sentences in the Koran which refer to the idea that the heart is the seat of moral sense and reason, 
of moral and spiritual life.  It is no mere coincidence that religious therapeutic objects (made of 
pieces of paper on which Koranic verses are written and wrapped in a piece of cloth) are 
frequently carried around the neck, over the heart, or that, on one occasion, a patient even took a 
cardiologist’s prescription, made two holes in it and slipped a string through them in order to 
wear it around his neck, over his heart. The importance given to the heart can also be seen when a 
Muslim nurse decided to choose another doctor for her child because the first one did not listen to 
the baby’s heart, or when a Muslim store manager considers that some doctors are not 
conscientious because they listen to patients’ hearts through their clothes.  
 Just as we have seen with the heart, there are a certain number of behaviours which can be 
explained by the desire to preserve certain functions or organs of the body, to which the drugs are 
suspected of posing a threat. This is the case with people from other cultural groups who also 
have reservations about psychotropic drugs, albeit for different reasons. What must be noted here 
is that the undesirable (physical, social, psychiatric and behavioural) effects of medications are 
not the same for everybody, despite what is explicitly stated in pharmaceutical inserts. 
 Among Protestants, the reluctance to take psychotropic drugs is often due to a fear of the 
dependency they create. It is interesting to note that the refusal of dependency is a core value 
among Protestants and that it also influences their general wish to manage their illness, their 
prescriptions and their treatments in a totally independent fashion. 
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 Reluctance among Jews to take psychotropic drugs is related to fear of the loss of memory that 
prolonged taking of this type of medication might induce. Among Jews, whether they are 
believers or not, memory is a cardinal value that must not be endangered.  The fact that memory 
is highly valued not only has something to do with the fact that religious instruction includes the 
obligation of memory since the destruction of the Temple, but can also be related to its links with 
History: remembering means protecting oneself. The history of persecutions experienced 
throughout the centuries and especially in the 20th century has reinforced this injunction to 
remember and to be wary.  The continued reference to memory recurs as a leitmotif in Jews' 
expression of the fear associated with taking psychotropic drugs. It must be stressed here that 
there is not always consistency between views and actual practices, in so far as patients 
sometimes take the drugs even when they are reluctant to do so. Yet even when they do take 
psychotropic drugs, many patients do not do it with a light heart, or else they try to diminish the 
doses of the prescribed drugs.   
 As we can see, all these dimensions bring into play both representations of the drug and 
representations of the person, and take into consideration the effects or the risks of drugs in their 
physical, psychic, behavioural and social aspects.  But other logics can be noted, in any type of 
cultural group.  Some choose to restrict the use of drugs to a certain number according to a logic 
which is not validated by doctors; patient vigilance here consists in limiting the number of 
pharmaceutical drugs to take in order to reduce risks of interaction, at the cost of a 
reinterpretation or a rearrangement of prescriptions.  But this can also happen within the 
framework of self-medication, where patients decide to prevent the drugs they use from 
interacting negatively, and base their choice on a quantitative logic. For instance, one school-
teacher considers that the number of drugs used must be limited to 3: “as soon as one takes more 
than 3 drugs, there are risks of interference”, she says. The iatrogenic risk here relates to the 
quantity rather than to the quality of the drugs. This is why when there are more than 3 drugs 
prescribed, she decides not to comply with the full prescription and chooses, from the list, a 
maximum of 3 which seem to her to be the most necessary. 
 Fear of the iatrogenic risks resulting from drug consumption causes some patients to refuse to 
practice self-medication, believing that the mix of drugs is dangerous, whereas on the other hand 
it is the need to be vigilant which leads other patients to want to acquire a medical understanding 
of drugs and to dream of software which might be used to see whether the drugs they wish to take 
are compatible.  
 Therefore, despite the supposedly high level of drug consumption in France, patients do not 
necessarily want to cumulate the drugs (that is to say to take the greatest possible number or 
quantity of drugs). Some patients prefer to ensure that the drugs they take suit their body and their 
being. Some patients have vigilance behaviours which consist in limiting the bad effects of drugs 
by trying to adapt them to their Self, according to logics which, once again, are not necessarily 
those of their doctors. This leads to a redefinition of dosages, which implies the recognition of a 
relationship between the drug and what the person is: fat or thin, strong or fragile, old or young, 
man or woman, etc., leading patients to either increasing or reducing the prescribed doses of 
drugs, dose reduction generally being motivated by the wish to reduce the harmful effects of 
drugs.  
 
 
Doctors’ discourses 
  
 Whilst patients are very keen to avoid the side-effects and risks of drugs, it is not rare for 
doctors to attempt to hide them. This leads us to consider doctors’ discourses within the 
framework of the doctor-patient relationship (and therefore, in concrete terms, of the 
consultation) concerning the risks related to certain drugs, and the place given to the contents of 
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the pharmaceutical insert, both in hospitals and in private consultations.  On this point, the data 
collected come partly from the study mentioned above, within the framework of private 
consultations for all types of pathology, and partly from another study carried out on the issue of 
information exchanged between doctors and patients in hospital departments (oncology and 
internal medicine). It covered 80 patients (sixty with cancer and twenty with other pathologies 
including chronic inflammatory illnesses or autoimmune illnesses) of different ages (between 30 
and 80 years old), of both sexes and from various socio-professional backgrounds. With the aim 
of the research being to highlight the logics and mechanisms at the root of information exchanges 
between doctors and patients, the investigation consisted in observing medical consultations and 
then separately meeting the doctors and the patients in order to see how the verbal exchanges 
were constructed and to decode the reasons and mechanisms of their acts and words.   
 Despite the Law on Patients’ rights of March 4, 2002, guaranteeing patient information, the 
observation of consultations shows that not only do medical doctors not provide full and 
complete information on the risks of a treatment, but that they sometimes choose to conceal the 
possible effects of drugs from patients, or even to deceive patients about these effects so that 
there is no risk of this information discouraging them from taking the prescribed drug or causing 
them not to comply with the prescribed treatment. Adopting an ironic stance in relation to the 
“shared decision” model, one doctor takes umbrage at the legal obligation to tell a patient about 
the risks of the treatment: “Why upset the patient when he might in any case die of renal or 
cardiac insufficiency if I do not give him the treatment? The shared decision system means 
shared anguish! We no longer have the right to prescribe cancerous drugs without telling 
patients, yet the risk is theoretical!” Another doctor explains: “With certain treatments there are 
risks for the kidneys; so I sometimes hide the side-effects of the drugs – for example, 
methotrexate can cause pulmonary fibrosis and with endoxan there’s a problem after 30 years: 
there is a risk of leukaemia. There’s no point telling them, or else they won’t take the treatment!”   
 Regarding treatments and their possible effects, we also observed forms of withholding 
information through the attitude of certain doctors who discouraged patients from reading the 
pharmaceutical instructions with the objective of encouraging compliance. “You read too much” 
was one doctor’s reproach to a patient who was worried about the adverse effects mentioned in a 
drug’s pharmaceutical insert, and about the quantity which he had been prescribed, which was 
greater than the dosage recommended in the insert. They tend not only to keep quiet about 
unpleasant side-effects so that such information does not discourage patients from taking the 
drugs and to ensure that they will be compliant, but sometimes even deny the information 
contained in the instructions. Indeed, some go so far as to assert that the content of inserts about 
possible effects is false, in order for the patients to submit to the prescription. What doctors 
choose to say to their patients about drugs varies widely, depending on the nature of the disorder 
being treated, but the dissimulation of the risks of certain drugs is found just as much in cases of 
benign pathologies as in serious pathologies. The practice thus consists in lying to the patient in 
the patient’s interest, within the framework of a doctor-patient relationship which remains 
paternalistic.  
 Here we approach the issue of the ethics of information. Our objective is not to comment on 
the ethical nature of the behaviours that are examined here - the ethical aspect of the issue of 
information and truth is very widely discussed in existing literature (9) (10). On the other hand, it 
is important to stress the place taken by ethics in doctors’ justifications for their practices, since 
some doctors choose to hide the effects of drugs from the patients – or even to lie to them on this 
subject – in order to not alarm them and with the aim of not jeopardizing their compliance, 
referring to what they consider to be ethical professional behaviour. This situation leads to 
confrontation between the two logics - ethics of care versus ethics of information – that they say 
they follow.  Doctors justify such an attitude in the name of the necessity of patient compliance, 
which constitutes a kind of paradox, both logical and ethical, since it is in the name of 
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compliance − identified as being in the patient’s interest − that doctors adopt a behaviour which 
is contrary to patient information on drugs and on their possible effects.  
 
The industry’s discourse  
 
 Another social actor must also be taken into consideration in this context:  the pharmaceutical 
industry.  Directly related to the issue of safety, it must be noted that the scandals which arose 
around drugs such as Vioxx resulted in patients mistrusting the industry’s discourse.  Just as 
patients have learnt to mistrust doctors because they know them to often dissimulate facts, some 
patients are distrustful of the pharmaceutical industry when they know that risks have been 
hidden.  They want to be “enlightened” in accordance with the modern notion of “patients’ 
rights”, and think that they should be clearly informed of any drug-related risks, especially when 
they need to resort to self-medication. 
 But now we come to what interests us most – the pharmaceutical industry’s discourse 
regarding self-medication in relation to the issue of safety.  The pharmaceutical industry − 
represented in particular by AFIPA (“Association Française de l’Industrie Pharmaceutique pour 
une Automédication responsible”, which means “French Association for the pharmaceutical 
industry for responsible self-medication”) and LEEM (“Les Entreprises du Médicament”, that is 
“The Pharmaceutical Companies”) − support the development of self-medication, which they 
define as “the spontaneous non-prescribed purchase of drugs at a pharmacy” (11).  Moreover, the 
industry is generally in favour of free access to drugs (that is to say over-the-counter drugs).  But, 
just like the authorities, the industry defends pharmacists’ monopoly on the distribution of drugs 
and advocates “encouraging doctors to assist in the promotion of self-medication”, in order to 
“allow them to supervise their patients’ drug consumption”.  
 Beyond the economic motives which are obviously at stake here, the industry is also 
attempting to take a stance at a human and philosophical level, by declaring that it is necessary to 
encourage “responsible self-medication” in order “to satisfy people’s increasing desire to take 
care of themselves and to be responsible for their health” (12), echoing the view of the Ministry 
of Health who declared, when promoting self-medication, that it is willing to “accompany 
patients in their will to be the actors of their health” (13). 
 Analysis of the industry’s discourses in this debate shows the extent to which it differs from 
the point of view of doctors, who are often opposed to self medication, precisely because of the 
risks involved.  The situation is one in which the pharmaceutical industry presents itself as the 
defender of users, affirmed in their autonomy, making the patients "responsible" individuals, 
asserting their rights and their competences.  However, there is one flaw in their discourse which 
shows that they do not have complete confidence in the ability of patients to be vigilant with 
regard to drugs.  We can perfectly understand that, commercially speaking, it is desirable that 
patients buy drugs and preferably ask the pharmacist rather than taking what they think they need 
from the medicine cabinet at home.  Yet whilst we might accept that the consumption of drugs 
without checking with the pharmacist may involve certain risks, the demonization of the family 
medicine cabinet testifies to the wish that patients stop using it, even though the medicine cabinet 
may contain what is appropriate for their problem.  The patient’s competence and aptitude for 
vigilance is here called into question.  Just like public policies, the industry is sending patients a 
somewhat contradictory message, recognizing their competence regarding vigilance towards 
drugs, whilst at the same time denying any such competence. 
 
Concluding remarks 
 
 The anthropological perspective doesn’t seek to impose a normative judgment on the 
phenomena it studies. But the analyses of behaviours and discourses of the social actors which are 
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on the scene (health professionals, patients and industry) show how the ones and the others set up 
strategies aiming at an optimal use of drugs, all concerned, each in their own way, in managing 
safety and efficacy, though those strategies are closely articulated with symbolic, ethical or 
cultural logics. 
 The way in which a society manages the issue of drug safety does not depend solely on 
pharmacovigilance data, but also on symbolic logics and cultural representations, even if these 
escape medical rationality. 
 An examination of the question of safe drug use and safety thus means studying the human 
(social and cultural) aspects which govern some of the attitudes and practices relating to drug 
safety.  On the basis of the three examples set out here, the analysis of the attitudes and practices 
of the different actors (patients, doctors, industry) regarding safe drug use by patients shows just 
how much they are underpinned by ideological, moral, social and symbolic aspects.  
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